Relapses were thought to drive disability progression with RRMS, but PIRA may be an important contributor, affecting patients ...

In relapsing-remitting multiple sclerosis (MS), all of the currently available disease-modifying medications are injectables marketed for self-injection. Problems with self-injection pose a ...

also known as relapsing-remitting MS (RRMS). According to the MS Society, in RRMS people have attacks of new and old symptoms, i.e. a relapse. RRMS is the most common type of multiple sclerosis ...

Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.